miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Docetaxel is a key chemotherapy for non-small cell lung cancer (NSCLC).
• Acquired chemoresistance remains a significant clinical challenge in NSCLC treatment.
• MicroRNAs (miRNAs) play crucial roles in cancer progression and drug resistance.

Purpose of the Study:

• To investigate the role of miR-141 in regulating eukaryotic initiation factor-4E (EIF4E) expression in docetaxel-resistant NSCLC.
• To elucidate the underlying molecular mechanisms of acquired docetaxel chemoresistance in NSCLC.
• To identify potential therapeutic targets for overcoming docetaxel resistance in NSCLC.

Main Methods:

• Analysis of miR-141 and EIF4E expression in docetaxel-resistant NSCLC patient samples.
• In vitro experiments using NSCLC cell lines (H1299, H2009) with acquired docetaxel resistance.
• Manipulation of miR-141 expression (downregulation and upregulation) to assess effects on cell proliferation, apoptosis, and protein expression.

Main Results:

• miR-141 expression was significantly higher, and EIF4E expression was lower in docetaxel-resistant NSCLC patients.
• Downregulation of miR-141 suppressed proliferation, induced apoptosis, and increased EIF4E, VEGF, c-Myc, and Bax protein levels.
• Upregulation of miR-141 promoted proliferation, inhibited apoptosis, and suppressed EIF4E, VEGF, c-Myc, and Bax protein levels.

Conclusions:

• The study identifies a novel miR-141/EIF4E regulatory axis in acquired docetaxel chemoresistance in NSCLC.
• This pathway, involving interactions with VEGF, c-Myc, and Bax, offers a potential mechanism for chemoresistance.
• Targeting the miR-141/EIF4E pathway presents a promising therapeutic strategy for overcoming docetaxel resistance in NSCLC.